Warning: The NCBI web site requires JavaScript to function. more...
Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis.
Zou Y, Tsai WB, Cheng CJ, Hsu C, Chung YM, Li PC, Lin SH, Hu MC.
Breast Cancer Res. 2008;10(1):R21. Epub 2008 Feb 29.
Related citations
P2Y2 receptor-mediated modulation of estrogen-induced proliferation of breast cancer cells.
Li HJ, Wang LY, Qu HN, Yu LH, Burnstock G, Ni X, Xu M, Ma B.
Mol Cell Endocrinol. 2011 May 16;338(1-2):28-37. Epub 2011 Feb 26.
Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells.
Fox EM, Bernaciak TM, Wen J, Weaver AM, Shupnik MA, Silva CM.
Mol Endocrinol. 2008 Aug;22(8):1781-96. Epub 2008 Jun 11.
Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
Chang HL, Sugimoto Y, Liu S, Ye W, Wang LS, Huang YW, Lin YC.
Anticancer Res. 2006 May-Jun;26(3A):1773-84.
Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA, Mehmi I, Atlas E, Colomer R, Lupu R.
Int J Oncol. 2004 Mar;24(3):591-608.
Decursin and decursinol angelate inhibit estrogen-stimulated and estrogen-independent growth and survival of breast cancer cells.
Jiang C, Guo J, Wang Z, Xiao B, Lee HJ, Lee EO, Kim SH, Lu J.
Breast Cancer Res. 2007;9(6):R77.
Akt2 inhibition enables the forkhead transcription factor FoxO3a to have a repressive role in estrogen receptor alpha transcriptional activity in breast cancer cells.
Morelli C, Lanzino M, Garofalo C, Maris P, Brunelli E, Casaburi I, Catalano S, Bruno R, Sisci D, Andò S.
Mol Cell Biol. 2010 Feb;30(3):857-70. Epub 2009 Nov 23.
Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor.
Weng SC, Kashida Y, Kulp SK, Wang D, Brueggemeier RW, Shapiro CL, Chen CS.
Mol Cancer Ther. 2008 Apr;7(4):800-8.
Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis.
Lewis-Wambi JS, Kim HR, Wambi C, Patel R, Pyle JR, Klein-Szanto AJ, Jordan VC.
Breast Cancer Res. 2008;10(6):R104. Epub 2008 Dec 5.
MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
Atanaskova N, Keshamouni VG, Krueger JS, Schwartz JA, Miller F, Reddy KB.
Oncogene. 2002 Jun 6;21(25):4000-8.
Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function.
Foster JS, Henley DC, Bukovsky A, Seth P, Wimalasena J.
Mol Cell Biol. 2001 Feb;21(3):794-810.
ERβ1 represses FOXM1 expression through targeting ERα to control cell proliferation in breast cancer.
Horimoto Y, Hartman J, Millour J, Pollock S, Olmos Y, Ho KK, Coombes RC, Poutanen M, Mäkelä SI, El-Bahrawy M, Speirs V, Lam EW.
Am J Pathol. 2011 Sep;179(3):1148-56. Epub 2011 Jul 16.
The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
Menendez JA, Oza BP, Colomer R, Lupu R.
Int J Oncol. 2005 Jun;26(6):1507-15.
Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha.
Chisamore MJ, Ahmed Y, Bentrem DJ, Jordan VC, Tonetti DA.
Clin Cancer Res. 2001 Oct;7(10):3156-65.
Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells.
Kawai H, Li H, Chun P, Avraham S, Avraham HK.
Oncogene. 2002 Oct 31;21(50):7730-9.
Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells.
Pietras RJ, Márquez DC, Chen HW, Tsai E, Weinberg O, Fishbein M.
Steroids. 2005 May-Jun;70(5-7):372-81. Epub 2005 Mar 25.
Up-regulation of LRP16 mRNA by 17beta-estradiol through activation of estrogen receptor alpha (ERalpha), but not ERbeta, and promotion of human breast cancer MCF-7 cell proliferation: a preliminary report.
Han WD, Mu YM, Lu XC, Xu ZM, Li XJ, Yu L, Song HJ, Li M, Lu JM, Zhao YL, Pan CY.
Endocr Relat Cancer. 2003 Jun;10(2):217-24.
Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway.
Guo S, Sonenshein GE.
Mol Cell Biol. 2004 Oct;24(19):8681-90.
Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human ER-positive breast cancer cells.
Węsierska-Gądek J, Gritsch D, Zulehner N, Komina O, Maurer M.
J Cell Biochem. 2011 Mar;112(3):761-72. doi: 10.1002/jcb.23004.
Activation of the estrogen-signaling pathway by p21(WAF1/CIP1) in estrogen receptor-negative breast cancer cells.
Chen X, Danes C, Lowe M, Herliczek TW, Keyomarsi K.
J Natl Cancer Inst. 2000 Sep 6;92(17):1403-13.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on